123 related articles for article (PubMed ID: 23023419)
1. [Effect of bisphosphonates on anticancer activity in prostate cancer cells].
Iguchi K
Yakugaku Zasshi; 2012; 132(9):1025-30. PubMed ID: 23023419
[TBL] [Abstract][Full Text] [Related]
2. Protein kinase C is inhibited by bisphosphonates in prostate cancer PC-3 cells.
Tatsuda Y; Iguchi K; Usui S; Suzui M; Hirano K
Eur J Pharmacol; 2010 Feb; 627(1-3):348-53. PubMed ID: 19903468
[TBL] [Abstract][Full Text] [Related]
3. Pamidronate inhibits antiapoptotic bcl-2 expression through inhibition of the mevalonate pathway in prostate cancer PC-3 cells.
Iguchi K; Tatsuda Y; Usui S; Hirano K
Eur J Pharmacol; 2010 Sep; 641(1):35-40. PubMed ID: 20519142
[TBL] [Abstract][Full Text] [Related]
4. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells.
Oades GM; Senaratne SG; Clarke IA; Kirby RS; Colston KW
J Urol; 2003 Jul; 170(1):246-52. PubMed ID: 12796698
[TBL] [Abstract][Full Text] [Related]
5. Incadronate inhibits aminopeptidase N expression in prostatic PC-3 cells.
Iguchi K; Nakano T; Usui S; Hirano K
Cancer Lett; 2006 Jun; 237(2):223-33. PubMed ID: 16019130
[TBL] [Abstract][Full Text] [Related]
6. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway.
Virtanen SS; Väänänen HK; Härkönen PL; Lakkakorpi PT
Cancer Res; 2002 May; 62(9):2708-14. PubMed ID: 11980672
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis.
Green JR; Clézardin P
Am J Clin Oncol; 2002 Dec; 25(6 Suppl 1):S3-9. PubMed ID: 12562045
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells.
Merrell MA; Wakchoure S; Lehenkari PP; Harris KW; Selander KS
Eur J Pharmacol; 2007 Sep; 570(1-3):27-37. PubMed ID: 17640631
[TBL] [Abstract][Full Text] [Related]
9. Pamidronate down-regulates urokinase-type plasminogen activator expression in PC-3 prostate cancer cells.
Iguchi K; Tatsuda Y; Usui S; Hirano K
Anticancer Res; 2007; 27(6B):3843-8. PubMed ID: 18225541
[TBL] [Abstract][Full Text] [Related]
10. Direct effects of bisphosphonates on breast cancer cells.
Senaratne SG; Colston KW
Breast Cancer Res; 2002; 4(1):18-23. PubMed ID: 11879555
[TBL] [Abstract][Full Text] [Related]
11. Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells.
Dumon JC; Journé F; Kheddoumi N; Lagneaux L; Body JJ
Eur Urol; 2004 Apr; 45(4):521-8; discussion 528-9. PubMed ID: 15041119
[TBL] [Abstract][Full Text] [Related]
12. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
Shipman CM; Croucher PI; Russell RG; Helfrich MH; Rogers MJ
Cancer Res; 1998 Dec; 58(23):5294-7. PubMed ID: 9850051
[TBL] [Abstract][Full Text] [Related]
13. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
[TBL] [Abstract][Full Text] [Related]
14. Potential anticancer properties of bisphosphonates.
Neville-Webbe HL; Gnant M; Coleman RE
Semin Oncol; 2010 Jun; 37 Suppl 1():S53-65. PubMed ID: 20682373
[TBL] [Abstract][Full Text] [Related]
15. Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity.
Suri S; Mönkkönen J; Taskinen M; Pesonen J; Blank MA; Phipps RJ; Rogers MJ
Bone; 2001 Oct; 29(4):336-43. PubMed ID: 11595616
[TBL] [Abstract][Full Text] [Related]
16. The effects on hTERT gene expression is an additional mechanism of amino-bisphosphonates in prostatic cancer cells.
Valenti MT; Dalle Carbonare L; Bertoldo F; Donatelli L; Lo Cascio V
Eur J Pharmacol; 2008 Feb; 580(1-2):36-42. PubMed ID: 18037402
[TBL] [Abstract][Full Text] [Related]
17. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates.
van beek E; Löwik C; van der Pluijm G; Papapoulos S
J Bone Miner Res; 1999 May; 14(5):722-9. PubMed ID: 10320520
[TBL] [Abstract][Full Text] [Related]
18. The molecular basis of bisphosphonate activity: a preclinical perspective.
Green J; Clézardin P
Semin Oncol; 2010 Jun; 37 Suppl 1():S3-11. PubMed ID: 20682369
[TBL] [Abstract][Full Text] [Related]
19. Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: identity of a potent new bisphosphonate analogue.
Reinholz GG; Getz B; Sanders ES; Karpeisky MY; Padyukova NSh; Mikhailov SN; Ingle JN; Spelsberg TC
Breast Cancer Res Treat; 2002 Feb; 71(3):257-68. PubMed ID: 12002344
[TBL] [Abstract][Full Text] [Related]
20. Incadronate induces cell detachment and apoptosis in prostatic PC-3 cells.
Matsunaga S; Iguchi K; Usui S; Hirano K
Anticancer Res; 2007; 27(2):927-32. PubMed ID: 17465222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]